We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Jessica
Hunt
jessica.hunt2@cancer.org.uk
Millie
Campbell
millie.campbell@cancer.org.uk
Dr
Matthew
Krebs
matthew.krebs@nhs.net
Miss
Helen
Wilkinson
helen.wilkinson@cancer.org.uk
Aida
Sarmiento Castro
aida.sarmientocastro@cancer.org.uk
Aida
Sarmiento Castro
aida.sarmientocastro@cancer.org.uk
Miss
Helen
Wilkinson
helen.wilkinson@cancer.org.uk
Jessica
Hunt
jessica.hunt2@cancer.org.uk
Malignant neoplasms of ill-defined, secondary and unspecified sites
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
The overall aim of the trial is to evaluate the efficacy of licensed targeted therapies in unlicensed indications,in rare adult,paediatric and TYA cancers with actionable genomic alterations (including common cancers with rare actionable alterations) and to identify genomic,transcriptomic and immune contextual influences on response to therapy. The ultimate aim is to transition positive findings to the NHS (Cancer Drugs Fund [CDF]) to provide new treatment options for patients with rare malignancies.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Drug;Immunotherapy;
You can take part if:
You may not be able to take part if:
The patient must fulfil the core eligibility criteria outlined below and within the specific treatment arm appendix to which they are enrolled. Core Exclusion Criteria 1. Ongoing adverse events >CTCAE Grade 2 attributable to previous anti-cancer treatments. Exceptions to this are any ongoing toxic manifestation,which in the opinion of the Investigator and the Sponsor Medical Advisor should not exclude the patient. 2. At high medical risk,in the opinion of the Investigator,because of non-malignant systemic disease (including active uncontrolled infection). 3. Female patients who are pregnant,breastfeeding or planning to become pregnant or male patients with a partner who is a woman of childbearing potential and is planning to become pregnant during the trial or following the last dose of IMP,as specified in each treatment arm appendix. 4. Is (or plans to be) a participant in another interventional clinical trial,whilst taking part in this trial. Participation in an observational trial which does not involve administration of an IMP and which,in the opinion of the local Investigator,would not place an unacceptable burden on the patient would be acceptable e.g. sample collection* or QoL studies. *for paediatric patients participating in other studies involving tissue/ctDNA/other blood collection,consideration would need to be given to the total blood volumes collected (as per the European Medicines Agency blood volume limits for children [8]). 5. Co-administration of anti-cancer therapies other than those administered in this trial. 6. Radiotherapy (except for palliative reasons) or chemotherapy,endocrine therapy,nitrosoureas,mitomycin-C,immunotherapy and molecularly targeted agents or other investigational medicinal products within 4 weeks or 5 half-lives (whichever is the shorter). Patients with rapidly progressing or symptomatically deteriorating brain metastases. Patients with previously treated brain metastases are eligible,provided the patient has not experienced a seizure or had a clinically significant change in neurological status within the two weeks prior to registration. Such patients must be non-dependent on steroids or on a stable or reducing dose of steroid treatment for at least 14 days (or 7 days for paediatric patients) prior to trial enrolment. Primary brain or CNS malignancies are allowed providing the patient is clinically stable (if requiring corticosteroids must be at stable or decreasing doses for at least 14 days for adults and 7 days for paediatric patients prior to the start of IMP administration). Patients who have received brain irradiation must have completed whole-brain radiotherapy and/or stereotactic radiosurgery at least 14 days prior to the start of IMP administration. 8. Any other condition which,in the opinion of the local Investigator,would not be in the best interests of the patient.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Miss
Helen
Wilkinson
helen.wilkinson@cancer.org.uk
Aida
Sarmiento Castro
aida.sarmientocastro@cancer.org.uk
Jessica
Hunt
jessica.hunt2@cancer.org.uk
Dr
Matthew
Krebs
matthew.krebs@nhs.net
Millie
Campbell
millie.campbell@cancer.org.uk
Aida
Sarmiento Castro
aida.sarmientocastro@cancer.org.uk
Miss
Helen
Wilkinson
helen.wilkinson@cancer.org.uk
Jessica
Hunt
jessica.hunt2@cancer.org.uk
The study is sponsored by CANCER RESEARCH UK and funded by CANCER RESEARCH UK; F. Hoffmann-La Roche Ltd; .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 52538
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
